Duloxetine Capsule, Delayed Release
Product Images NDC 71610-954

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-954). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0954 30)

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure1 (Duloxetine Fig1)

This data represents the number of patients with relapse over time after receiving either placebo or duloxetine treatment. The x-axis shows the time from randomization to relapse in days, ranging from 0 to 250 days. Placebo and duloxetine are compared in terms of their effectiveness in preventing relapse in patients.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This description provides information regarding the dosage of Duloxetine at 60/120 mg once daily in comparison to a placebo for pain management. It also includes a visual representation of the percent improvement in pain from the baseline.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This text appears to describe a graph showing the proportion of patients experiencing a relapse over time for two different treatments: Placebo and Duloxetine. The x-axis represents the time from randomization to relapse in days, while the y-axis shows the proportion of patients with relapse. The graph shows the trend of relapse rates for each treatment over the specified time period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

The text provides information about the percentage of patients improved with different doses of Duloxetine and Placebo medication. It includes measurements of improvement in pain from the baseline. The data can be used to evaluate the effectiveness of different dosages in managing pain symptoms.*

FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

This text provides data on the percentage of patients who showed improvement in pain levels based on different treatment options: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and Placebo. The chart shows a 100-point scale indicating the percent improvement in pain from baseline for each treatment option.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

This data table shows the percentage of patients improved with Duloxetine 60 mg once daily treatment compared to Placebo. The percentage of improvement ranges from 0 to 100, with a higher percentage indicating greater pain relief from baseline.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This text provides information about the dosage of Duloxetine (60/120 mg once daily) compared to a Placebo. It also mentions a percent improvement in pain from baseline.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This text mentions a study comparing the use of placebo with Duloxetine at a dosage of 60 mg once daily. It also indicates the percentage improvement in pain from the baseline, using the BOCF method.*

FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.